Why Patient-Focused Drug Development Should Drive Corporate Strategy

In October 2025, the US Food and Drug Administration released four interrelated guidance documents on patient-focused drug development, including “Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.” Taken together, the documents give biopharma companies detailed practical direction on how to identify, select, and measure outcomes that matter to patients. What they do not address is the harder question of how leadership should integrate patient-centered thinking into product development strategy and corporate decision-making. That gap is worth closing because patient focus, properly applied, is not a regulatory obligation – it is one of the most effective tools available for building a commercially successful company.